These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. Hussein N; Weng SF; Kai J; Kleijnen J; Qureshi N Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010849. PubMed ID: 26264938 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic heteroduplexes: simple detection of carriers of a 4-bp insertion mutation in Tay-Sachs disease. Triggs-Raine BL; Gravel RA Am J Hum Genet; 1990 Jan; 46(1):183-4. PubMed ID: 2294750 [No Abstract] [Full Text] [Related]
5. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. Barlow-Stewart K; Burnett L; Proos A; Howell V; Huq F; Lazarus R; Aizenberg H J Med Genet; 2003 Apr; 40(4):e45. PubMed ID: 12676918 [No Abstract] [Full Text] [Related]
6. Multimedia messages in genetics: design, development, and evaluation of a computer-based instructional resource for secondary school students in a Tay Sachs disease carrier screening program. Gason AA; Aitken M; Delatycki MB; Sheffield E; Metcalfe SA Genet Med; 2004; 6(4):226-31. PubMed ID: 15266211 [TBL] [Abstract][Full Text] [Related]
7. Prenatal exclusion of Tay-Sachs disease by DNA analysis. Triggs-Raine BL; Archibald A; Gravel RA; Clarke JT Lancet; 1990 May; 335(8698):1164. PubMed ID: 1971898 [No Abstract] [Full Text] [Related]
8. Polymerase chain reaction-generated heteroduplexes from Ashkenazi Tay-Sachs carriers with an insertion mutation can be detected on agarose gels. Shore S; Myerowitz R Am J Hum Genet; 1990 Jul; 47(1):169. PubMed ID: 2349947 [No Abstract] [Full Text] [Related]
9. Effects of genetic screening on perceptions of health: a pilot study. Marteau TM; van Duijn M; Ellis I J Med Genet; 1992 Jan; 29(1):24-6. PubMed ID: 1552538 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. Warren E; Anderson R; Proos AL; Burnett LB; Barlow-Stewart K; Hall J Genet Med; 2005 Sep; 7(7):484-94. PubMed ID: 16170240 [TBL] [Abstract][Full Text] [Related]
11. One worked; the other didn't. Roberts L Science; 1990 Jan; 247(4938):18. PubMed ID: 2294586 [No Abstract] [Full Text] [Related]
13. The incidence and carrier frequency of Tay-Sachs disease in the French-Canadian population of Quebec based on retrospective data from 24 years, 1992-2015. Sillon G; Allard P; Drury S; Rivière JB; De Bie I J Genet Couns; 2020 Dec; 29(6):1173-1185. PubMed ID: 32302469 [TBL] [Abstract][Full Text] [Related]
14. Carrier screening for Tay-Sachs disease and cystic fibrosis. ten Kate LP; Tijmstra T Lancet; 1990 Jun; 335(8704):1527-8. PubMed ID: 1972454 [No Abstract] [Full Text] [Related]
15. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews. DeMarchi JM; Caskey CT; Richards CS Hum Mutat; 1996; 8(2):116-25. PubMed ID: 8844209 [TBL] [Abstract][Full Text] [Related]
16. Stigmatization of carrier status: social implications of heterozygote genetic screening programs. Kenen RH; Schmidt RM Am J Public Health; 1978 Nov; 68(11):1116-20. PubMed ID: 152585 [TBL] [Abstract][Full Text] [Related]
18. On the perpetuation of relic genes having an inviable homozygote. Koeslag JH; Schach SR Ann Hum Genet; 1985 Oct; 49(4):291-302. PubMed ID: 4073837 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of a targeted genetic screening program for adolescents. McCabe L Am J Hum Genet; 1996 Oct; 59(4):762-3. PubMed ID: 8808589 [No Abstract] [Full Text] [Related]